Northland Securities analyst Carl Byrnes maintained a Buy rating on Amarin (NASDAQ:AMRN) Corporation Plc on Thursday, setting a price target of $15, which is approximately 197.62% above the present share price of $5.04.
Byrnes expects Amarin Corporation Plc to post earnings per share (EPS) of $0.00 for the third quarter of 2020.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in Amarin, with an average price target of $14.75.
The analysts price targets range from a high of $35 to a low of $8.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $135.32 million and a net profit of $4.16 million. The company's market cap is $1.96 billion.
According to TipRanks.com, Northland Securities analyst Carl Byrnes is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -12.7% and a 30.56% success rate.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.